Topas Therapeutics GmbH’s Post

🚀 Charting the Future of #ImmuneTolerance: Topas Therapeutics GmbH Therapeutics believes to be an Undiscovered Gem 💎   TOPAS Therapeutics is on a mission to redefine the treatment landscape for #autoimmunediseases. Guided by an innovative platform they want to unlock the transformative potential of immune tolerance with cutting-edge #nanoparticle technology at its core. The platform targets specific liver cells to induce tolerance—bringing precision and control to diseases like #celiac disease and beyond.   Their Phase 2a clinical trial results for #TPM502 in celiac disease now showcased persistent clinical benefits and promising outcomes, positioning the company as trailblazers in this competitive field. While the #biotech environment remains challenging, TOPAS sees unparalleled opportunities …   … or as CEO Hugo Fry puts it: “We still believe we’re an undiscovered gem.” With a robust foundation of results and supportive #investors, TOPAS wants to pave the way for a future where targeted therapies transform patient outcomes. We spoke to CEO Mr. Hugo Fry at #BIOEurope in Stockholm about TOPAS‘ technology, strategic challenges, and the future of immune tolerance. Read more about this on Plattform Life Sciences: https://lnkd.in/eVunciXA #BiotechInnovation #Investment #Financing Thanks to Eva Mulder from Trophic Communications

If you have a moment, read my thoughts on the future of immune tolerance at Topas Therapeutics GmbH

Our Chairman and Chief Executive Officer, Harvey Berger, M.D., will be chairing the upcoming panel on accelerating drug discovery at the annual Longwood Healthcare Leaders #BostonCEO forum, to be held at the Mandarin Oriental Hotel, Boston, October 28-29, 2024. The panel will address how leading companies are translating complex human biology into new therapeutics, expediting the drug discovery process, innovating and identifying new technologies, targets, and medicines, expanding company portfolios, and leveraging partners’ expertise in discovery initiatives. Specific topics will include pan-KRAS inhibitors, localizing molecular glues, new uses of CRISPR, therapeutic options for modulating ferroptosis and cell-state, and new biological approaches to discovery. The two-day, industry-leading meeting, chaired by Christoph Westphal, focuses on a broad spectrum of topics affecting the biopharma ecosystem. Decision makers in the life sciences, including biotech and pharma CEOs, heads of research and development, leading academics, and investors will discuss some of the most important issues facing healthcare today. Information and registration: https://lnkd.in/eehfZ2xB.     Kestrel Therapeutics | Cullinan Therapeutics | Excision BioTherapeutics | Magnet Biomedicine | Longwood Fund | Kojin Therapeutics | Brian Safina | Frank Haluska | Daniel Dornbusch | Jennifer Michaelson #ferroptosis #redox #KRAS #molecularglues #CRISPR #drugdiscovery #cancer #immunology #infectiousdisease #platforms #innovation #smallmolecule #biopharma #biotech #boston

Avidity Biosciences (RNA) leads in RNA therapeutics with Del-desiran (AOC 1001), targeting myotonic dystrophy type 1. Pivotal trial soon; approval could significantly boost earnings. Partnership with Bristol Myers Squibb, worth up to $2.3 billion, expands collaboration. Major clinical update for AOC 1001 expected by mid-2025; success could validate Avidity’s platform. Bullish on RNA above $24.00-$24.50, targeting $34.00-$35.00. Avidity's innovative approach presents significant growth potential. #AvidityBiosciences #RNA #Biotech #MyotonicDystrophy #ClinicalTrials #Innovation #Investing

[PRESS RELEASE] 📢 We are pleased to announce a strategic collaboration with Smart Immune, a clinical-stage biotechnology company! Together we will expand the production capabilities of an innovative therapy in Phase I/II trials for patients with acute leukemia or primary immunodeficiencies (PID), in the EU and the US. CELLforCURE by Seqens brings a robust and strongly established commercial manufacturing experience, positioning itself as a highly reliable partner for Smart Immune. 🎙️ “𝑊𝑒 𝑎𝑟𝑒 𝑣𝑒𝑟𝑦 𝑝𝑟𝑜𝑢𝑑 𝑡𝑜 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑒 𝑤𝑖𝑡ℎ 𝑆𝑚𝑎𝑟𝑡 𝐼𝑚𝑚𝑢𝑛𝑒 𝑎𝑛𝑑 𝑐𝑜𝑛𝑡𝑟𝑖𝑏𝑢𝑡𝑒 𝑡𝑜 𝑡ℎ𝑒 𝑎𝑚𝑏𝑖𝑡𝑖𝑜𝑛 𝑜𝑓 𝑏𝑟𝑖𝑛𝑔𝑖𝑛𝑔 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙 𝑡ℎ𝑒𝑟𝑎𝑝𝑖𝑒𝑠 𝑡𝑜 𝑚𝑜𝑟𝑒 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠,” says Pierre-Noël LIRSAC, President of CELLforCURE. “𝐶𝐸𝐿𝐿𝑓𝑜𝑟𝐶𝑈𝑅𝐸 𝑤𝑖𝑙𝑙 𝑙𝑒𝑣𝑒𝑟𝑎𝑔𝑒 𝑖𝑡𝑠 ℎ𝑖𝑠𝑡𝑜𝑟𝑖𝑐𝑎𝑙 𝑒𝑥𝑝𝑒𝑟𝑡𝑖𝑠𝑒 𝑎𝑠 𝑎 𝐶𝐷𝑀𝑂 𝑎𝑠 𝑤𝑒𝑙𝑙 𝑎𝑠 𝑖𝑡𝑠 “𝑟𝑒𝑎𝑙-𝑙𝑖𝑓𝑒” 𝑒𝑥𝑝𝑒𝑟𝑖𝑒𝑛𝑐𝑒 𝑡𝑜 𝑚𝑎𝑛𝑢𝑓𝑎𝑐𝑡𝑢𝑟𝑒 𝑆𝑀𝐴𝑅𝑇101 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑏𝑎𝑡𝑐ℎ𝑒𝑠.” ➡️ Read the full press release : https://lnkd.in/deG28Xfu 👏 Congratulations to all the teams involved in this promising partnership announced just one year after the acquisition of CELLforCURE by SEQENS! Karine Rossignol Pierre Heimendinger Centre MEARY AP-HP Greater Paris University Hospitals - AP-HP #cellforcure #smartimmune #celltherapy #biotech #innovativetherapies #smartimmune

🚀 Versant Ventures Launches Helicore Biopharma with $65M to Advance Obesity Treatments Just two months after introducing Pep2Tango Therapeutics, Versant Ventures is backing another obesity-focused biotech. Launching Helicore Biopharma, alongside OrbiMed, with a $65M Series A to develop next-gen obesity therapies. 🔹 HCR-188: A monoclonal antibody targeting GIP, showing promising preclinical results when combined with GLP-1 for enhanced fat loss & lean mass preservation. 🔹 HCR-488 & HCR-588: Incretin-based therapies advancing toward preclinical development. By blocking GIP signaling in the brain, Helicore aims to restore leptin sensitivity, improve satiety, and reduce fat deposition, addressing long-term patient needs beyond just weight loss. With support from Longitude Capital, Wellington Management, and Versant’s Ridgeline discovery engine, Helicore is poised to drive innovation in obesity treatment. It looks like funding within obesity isn't slowing down anytime soon! 🔬💊 #Biotech #ObesityTreatment #GLP1 #GIP #LifeSciences #Innovation

ImmPharma shares rocket on autoimmune breakthrough @ImmuPharma #AIM #IMM. ImmuPharma PLC (AIM:IMM) shares rocketed in early trading on Thursday following groundbreaking findings from its preclinical research focused on autoimmune diseases. The advancements, led by the company’s R&D subsidiary, ImmuPharma Biotech, highlighted novel insights into the mechanisms of autoimmune diseases and enhanced the potential of its therapeutic asset, P140. Key benefits from the research include improved diagnostic accuracy, better identification of patients likely to benefit from P140 therapy, and enhanced monitoring of treatment responses. The results point to progress... http://ow.ly/5AHI105WmeG

ImmuPharma shares rocket 200% on autoimmune breakthrough @ImmuPharma #AIM #IMM. ImmuPharma PLC (AIM:IMM) shares rocketed on Thursday following groundbreaking findings from its preclinical research focused on autoimmune diseases. The advancements, led by the company’s R&D subsidiary, ImmuPharma Biotech, highlighted novel insights into the mechanisms of autoimmune diseases and enhanced the potential of its therapeutic asset, P140. Key benefits from the research include improved diagnostic accuracy, better identification of patients likely to benefit from P140 therapy, and enhanced monitoring of treatment responses. The results point to progress towards... http://ow.ly/kjCQ105WnEA

CRISPR Therapeutics (CRSP) is making waves in the biotech space with its innovative gene-editing treatments. The company’s first commercial product, Casgevy, is revolutionizing the treatment of sickle cell disease and beta-thalassemia, with a potential to surpass $1 billion in annual sales. As the first-ever CRISPR-based gene-editing therapy, this milestone positions CRISPR Therapeutics as a leader in the field. Beyond Casgevy, the company has a promising pipeline of therapies, including CTX112, a potential treatment for B-cell malignancies, recently granted the FDA’s RMAT designation. While the biotech sector is inherently risky, CRISPR’s early success shows their expertise in delivering innovative, life-changing treatments. For those willing to embrace the volatility, CRSP presents a unique growth opportunity. #Biotech #GeneEditing #CRSP #Investment #HealthcareInnovation #StockMarket #GeneTherapy #stocks

Summary: Cartesian Therapeutics, a biotech company, successfully conducted a Phase 2 trial with its experimental therapy for myasthenia gravis, showing promising results in improving patients' conditions. The company plans to further discuss the data with US regulators and has initiated another Phase 2 study for systemic lupus erythematosus. Additionally, Cartesian raised $130 million in funding and appointed Kemal Malik to its board. Hashtags: #CartesianTherapeutics #AutoimmuneDisease #CellTherapy #BioTech #ClinicalTrials Read more here: https://lnkd.in/eiTx4Wb4 BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.